Danaher (DHR) Earnings Date & Reports

Key Takeaways

• Danaher reported third-quarter 2026 revenue of $6.55 billion, up 8.3% year over year and roughly in line with analyst consensus.
• Adjusted diluted earnings per share (EPS) reached $2.11, up 12% from a year earlier and well above the consensus estimate of $1.92.
• Core revenue grew 3.0%, accelerating to 5.5% when excluding the declining respiratory testing business.
• Adjusted operating margin expanded 110 basis points to 29.0%, led by a sharp improvement in the Biotechnology segment.
• Management raised full-year 2026 adjusted EPS guidance to $8.57–$8.62, up from a prior range of $8.45–$8.60.

Earnings Context and Why It Matters

Danaher's third-quarter report matters because it offers one of the clearest reads yet on the health of the life sciences and diagnostics end markets, including bioprocessing demand from pharmaceutical and biotechnology customers. After several quarters of uneven growth, investors have been watching closely for evidence that the company's base business is re-accelerating. The results also mark the first full reporting cycle under new Chief Executive Officer Julie Sawyer Montgomery, who assumed the role only weeks before the release. With the integration of the Masimo acquisition still underway and respiratory testing normalizing from elevated levels, this quarter helps separate durable core momentum from temporary headwinds.

Reported Results

For the three months ended September 25, 2026, Danaher reported revenue of $6.55 billion, an 8.3% increase from $6.05 billion in the prior-year period. Adjusted diluted EPS came in at $2.11, up 12% from $1.89 a year ago and ahead of the consensus estimate of $1.92. On a generally accepted accounting principles (GAAP) basis, diluted EPS from continuing operations rose 35% to $1.71, and net earnings from continuing operations increased 35% to $1.21 billion.

Core revenue growth was 3.0%, but excluding the normalization of respiratory testing, core growth accelerated to 5.5%. The company generated $1.6 billion in free cash flow during the quarter, a 19% increase from a year earlier.

By segment, Biotechnology revenue was $1.81 billion, up 5.0% on a core basis, with adjusted operating margin expanding 460 basis points to 41.8%. Life Sciences revenue of $1.87 billion grew 4.5% on a core basis. Diagnostics revenue of $2.88 billion rose 17.0% on a reported basis, reflecting the Masimo acquisition, and grew 7.0% on a core basis excluding respiratory testing.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can also help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following companies like Danaher, it offers a structured way to monitor comparable life sciences and diagnostics names. Explore the AI Screener to see how it can support your own research workflow.

Market Reaction and Investor Sentiment

Market reaction around the release was mixed but leaned positive. Some early trading reports showed shares initially dipping in premarket activity, while others indicated the stock subsequently moved higher as investors weighed the better-than-expected profitability and raised guidance. The key sentiment driver was the gap between Danaher's $2.11 adjusted EPS and the $1.92 consensus, alongside the upward revision to full-year earnings guidance. Investors also appeared encouraged by the 5.5% core growth excluding respiratory testing, which suggested underlying momentum in bioprocessing and diagnostics even as respiratory revenue remained a drag. The main sources of caution were the continued respiratory headwinds and modest reported core growth at the total-company level.

Forward Outlook and Key Factors to Monitor

Looking ahead, Danaher guided for fourth-quarter core revenue growth of 4% to 5% excluding respiratory testing, with respiratory revenue expected to subtract roughly 150 basis points, resulting in total core growth of approximately 3%. For the full year, the company now expects adjusted EPS of $8.57 to $8.62, implying double-digit growth over 2025.

Investors should monitor whether bioprocessing order trends continue to improve. In the third quarter, biotechnology orders rose mid-teens, with strength in upstream consumables and resins, a signal that could support accelerating growth into 2027. The pace of the Masimo integration in Diagnostics also remains a factor, given its dilutive impact on segment margins during the current integration phase.

Additional areas to watch include the trajectory of respiratory testing revenue, which management expects to reach roughly $1.5 billion for 2026, down about 20% from 2025, and any updates on academic research demand, which has remained below historical levels. Capital allocation, free cash flow conversion, and the new CEO's strategic priorities are also likely to shape investor expectations in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations